- Home
- STRO vs ENGN Comparison
STRO vs ENGN Comparison
Compare STRO & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- ENGN
- Stock Information
- Founded
- STRO 2003
- ENGN 1999
- Country
- STRO United States
- ENGN Canada
- Employees
- STRO N/A
- ENGN N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- ENGN
- Sector
- STRO Health Care
- ENGN
- Exchange
- STRO Nasdaq
- ENGN Nasdaq
- Market Cap
- STRO 292.6M
- ENGN 293.1M
- IPO Year
- STRO 2018
- ENGN N/A
- Fundamental
- Price
- STRO $2.75
- ENGN $8.60
- Analyst Decision
- STRO Strong Buy
- ENGN Strong Buy
- Analyst Count
- STRO 7
- ENGN 8
- Target Price
- STRO $12.14
- ENGN $30.38
- AVG Volume (30 Days)
- STRO 851.5K
- ENGN 72.6K
- Earning Date
- STRO 11-13-2024
- ENGN 01-27-2025
- Dividend Yield
- STRO N/A
- ENGN N/A
- EPS Growth
- STRO N/A
- ENGN N/A
- EPS
- STRO N/A
- ENGN N/A
- Revenue
- STRO $160,955,000.00
- ENGN N/A
- Revenue This Year
- STRO N/A
- ENGN N/A
- Revenue Next Year
- STRO N/A
- ENGN N/A
- P/E Ratio
- STRO N/A
- ENGN N/A
- Revenue Growth
- STRO 230.90
- ENGN N/A
- 52 Week Low
- STRO $2.45
- ENGN $4.42
- 52 Week High
- STRO $6.13
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- STRO 37.42
- ENGN 62.01
- Support Level
- STRO $2.55
- ENGN $8.20
- Resistance Level
- STRO $2.76
- ENGN $9.15
- Average True Range (ATR)
- STRO 0.27
- ENGN 0.54
- MACD
- STRO -0.05
- ENGN 0.09
- Stochastic Oscillator
- STRO 15.87
- ENGN 72.39
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.